摘要
目的研究头孢曲松/舒巴坦(CRO/SBT)及CRO单剂对四川地区临床分离致病菌的体外抗菌活性。方法采用琼脂二倍稀释法测定263株临床分离致病菌的最低抑菌浓度(MIC),观察细菌接种量、培养基pH及血清蛋白含量对体外抗菌活性的影响。结果 CRO/SBT联用可使金黄色葡萄球菌、表皮葡萄球菌、粪肠球菌、大肠埃希菌(产ESBLs)、铜绿假单胞菌、阴沟肠杆菌、肺炎克雷伯菌(产ESBLs)和鲍曼不动杆菌从单用CRO的MIC50值64～>256 mg.L-1降至4～32 mg.L-1,降幅达8～16倍。结论 CRO/SBT联合配伍使用的抗菌效果优于单用,CRO/SBT(4∶1)配方为较合理的复方制剂。
OBJECTIVE To study in vitro antibacterial activities of ceftriaxone（CRO） and ceftriaxone/ slbactan（CRO/SBT） with different ratios（1：1,2：1,4：1,8：1） against clinically isolated pathogenic bacteria from Sichuan province.METHODS The minimal inhibitory concentration（MIC） was determined by agar dilution method on 263 clinically isolated pathogenic bacteria.The influcences of the inoculum size,pH value and concentration of serum protein on in vitro antibacterial activity were observed.RESULTS MIC50 of CRO/SBT with different ratios against Staphylococcus aureus,Staphylococcus epidermidis,Enterococcus faecalis,Escherichia coli ESBLs,Pseudomonas aeruginosa,Aerobacter cloacae,Klebsiella pneumoniae ESBLs and Baumanii were 4-32 mg·L-1,which were 8-16 times lower than that of CRO alone.CONCLUSION Different formulas of CRO/SBT showed higher antibacterial activity against most clinical isolates than CRO alone in vitro when the ratio of CRO/SBT was 4：1.It was thought to a reasonable compound preparation.
出处
《华西药学杂志》
CAS
CSCD
北大核心
2011年第1期49-51,共3页
West China Journal of Pharmaceutical Sciences
